Australia markets closed

Alterity Therapeutics Limited (ATH.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
0.0050+0.0005 (+11.11%)
At close: 03:46PM AEDT
Full screen
Previous close0.0045
Open0.0045
Bid0.0040 x N/A
Ask0.0050 x N/A
Day's range0.0045 - 0.0050
52-week range0.0030 - 0.0090
Volume20,524,121
Avg. volume6,475,702
Market capN/A
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-0.0060
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

    MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme. The cash refund relates to the cost of e

  • GlobeNewswire

    Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

    – Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that thr

  • GlobeNewswire

    Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

    - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its second review of trial data and recommended the ATH